Company Overview and News

1
Crumbling Infrastructure Offers Mid-Market Investment Opportunities

2018-06-05 seekingalpha
Deteriorating infrastructure and potential for investment is the topic of a new white paper by Fiera Capital, a Canadian investment management firm.
MBL FSZ

0
Why this $100-billion fund manager thinks the TSX is about to bounce back

2018-04-11 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
FSZ TXCX

0
This $100 Billion Fund Manager Says Canadian Stocks Are About to Bounce - Bloomberg

2018-04-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FSZ TXCX

29
Equity Hedge Funds Must ‘Put Up or Shut Up’ With Market Volatility - Bloomberg

2018-04-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
WFC WFCNP WFC.WS FSZ WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

0
Oil, stocks rebound as China trade war scare ebbs

2018-04-04 themalaymailonline
Stocks on Wall Street and in Europe pulled back from more than 1 per cent declines, with the FTSE in London closing higher as the three major US indexes later turned positive. — Reuters picNEW YORK, April 5 — Oil edged higher and stocks on Wall Street recouped steep initial losses yesterday after China retaliated in a trade spat with the United States, but investors set aside concerns as any impact from a budding tariff war is still unknown.
FSZ

0
GLOBAL MARKETS-Oil, stocks rebound as China trade war scare ebbs

2018-04-04 reuters
NEW YORK, April 4 (Reuters) - Oil edged higher and stocks on Wall Street recouped steep initial losses on Wednesday after China retaliated in a trade spat with the United States, but investors set aside concerns as any impact from a budding tariff war is still unknown.
FSZ

0
BRIEF-Fiera Capital Acquires Investment Firm CGOV Asset Management

2018-03-23 reuters
* FIERA CAPITAL CORP - UNDER TERMS OF ASSET PURCHASE AGREEMENT FOR TRANSACTION, PURCHASE PRICE TOTALS $114.2 MILLION
FSZ

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...